Chemerin is a chemotactic protein that binds to the G protein -coupled receptor, ChemR23. We demonstrate that murine chemerin possesses potent antiinfl ammatory properties that are absolutely dependent on proteolytic processing. A series of peptides was designed, and only those identical to specifi c C-terminal chemerin sequences exerted antiinfl ammatory effects at picomolar concentrations in vitro. One of these, chemerin15 (C15; A 140 -A 154 ), inhibited macrophage (M ⌽ ) activation to a similar extent as proteolyzed chemerin, but exhibited reduced activity as a M ⌽ chemoattractant. Intraperitoneal administration of C15 (0.32 ng/kg) to mice before zymosan challenge conferred signifi cant protection against zymosan-induced peritonitis, suppressing neutrophil (63%) and monocyte (62%) recruitment with a concomitant reduction in proinfl ammatory mediator expression. Importantly, C15 was unable to ameliorate zymosan-induced peritonitis in ChemR23 ؊ / ؊ mice, demonstrating that C15 ' s antiinfl ammatory effects are entirely ChemR23 dependent. In addition, administration of neutralizing anti-chemerin antibody before zymosan challenge resulted in a signifi cant exacerbation of peritoneal infl ammation (up to 170%), suggesting an important endogenous antiinfl ammatory role for chemerin-derived species. Collectively, these results show that chemerin-derived peptides may represent a novel therapeutic strategy for the treatment of infl ammatory diseases through ChemR23.
BRIEF DEFINITIVE REPORT
Macrophages (M ⌽ s) are key participants in innate immunity and contribute to the infl ammatory response in part through the secretion of chemokines and cytokines that recruit and activate other immune cells. Despite the benefi cial role of infl ammatory mediators in host defense, their sustained production can lead to serious, chronic pathological conditions, such as atherosclerosis and rheumatoid arthritis. Therefore, although necessary for the elimination of pathogens, excessive and prolonged M ⌽ activation leads to serious deleterious eff ects in the host ( 1, 2 ) .
Chemerin is a chemoattractant protein present in a range of human infl ammatory exudates, including ascitic and synovial fl uid ( 3, 4 ) . Human prochemerin is secreted as a 142 -amino acid (aa) precursor (145-aa Mus musculus ), which undergoes C-terminal truncation to generate a 136-aa chemoattractant, chemerin (139-aa Mus musculus ) ( 3, 5 -7 ) . Chemerin was identifi ed as a natural ligand for the orphan heptahelical receptor ChemR23 through G protein -coupled receptor (GPCR) screening assays.
ChemR23 is a G ␣ i -linked receptor expressed primarily by monocytes, M ⌽ s, and plasmacytoid dendritic cells ( 7, 8 ) . ChemR23 shares phylogenetic homology with other chemoattractant receptors, including those for the antiinfl ammatory mediator lipoxin A 4 and the neutrophil chemotaxins C5a and C3a ( 3, 7, 9 ) . Extracellular terminal proteolysis is characteristic of ligands for some of these related receptors and appears to be used to modulate ligand bioactivites ( 3, 7, 9 ) . At the time of writing, another receptor for chemerin, the GPCR GPR1, has been identifi ed ( 10 ) .
In addition to chemerin, ChemR23 binds an eicosapentenoic acid -derived lipid termed resolvin E1 (RvE1) ( 11 ) . RvE1 is thought to exert antiinfl ammatory eff ects through activation of ChemR23 and has recently been found to be a ligand for the related receptor BLT1 ( 12 ) . RvE1 suppresses infl ammation in animal Design of chemerin peptides and assays for their bioactivity Previous studies have indicated that the biological activity of chemerin depends upon C-terminal processing ( 6, 14 ) . We therefore postulated that peptides formed upon C-terminal truncation could be responsible for the observed proteolysisdependent eff ects of chemerin on M ⌽ activation. Conserved residues were identifi ed by aligning the sequences of putative chemerin orthologs from several species using the ClustalW algorithm. A series of 11 -20-aa peptides was designed and named C11 (P 144 -A 154 ; PHGYFLPGQFA), C13 (P 144 -S 156 ; PHGYFLPGQFAFS), C15 (A 140 -A 154 ; AGEDPHGYFLP-GQFA), C19 (A 138 -S 156 ; AQAGEDPHGYFLPGQFAFS), N19 (E 23 -K 41 ; ELSETQRRSLQVALEEFHK), and M20 (K 86 -K 105 ; KPECTIKPNGRRRKCLACIK). C-terminal peptides C13 and C19 moderately suppressed LPS/IFN-␥ -induced RANTES and TNF-␣ expression with an optimal dose of 100 pM ( Table I ). Chemerin15 (C15), however, retained the antiinfl ammatory activity shown by proteolyzed chemerin and inhibited cytokine expression with similar effi cacy and potency as chemerin (optimal dose, 1 pM). In addition, C11, the N-terminal peptide (N19), midstream peptide (M20), and the control peptides (scrambled C15 [C15-S], GLFHDQAGPPA-GYEF, and mutant C15 [C15-M], AGEDPHGY A LPGQ A A) were devoid of antiinfl ammatory activity in the M ⌽ activation assay. The 6-aa (R 157 -K 162 ; RALRTK) and 8-aa (F 155 -K 162 ; FSRALRTK) peptides removed during prochemerin cleavage by proteases during coagulation, allergy, and tissue injury ( 5 ), named C6 and C8, respectively, also possessed no detectable antiinfl ammatory activity in the M ⌽ activation assay.
M ⌽ chemoattractant properties of chemerin and its C-terminal -derived peptides
We confi rmed previous reports that murine chemerin is a M ⌽ chemoattractant in modifi ed Boyden chamber assays over a dose range of 10 pM to 50 nM ( Fig. S1 A, available at http:// www.jem.org/cgi/content/full/jem.20071601/DC1). C11, C13, and C15 (1 pM -100 nM; Fig. S1 , B -D) possessed little M ⌽ chemotactic activity compared with chemerin or a positive control, the CC chemokine RANTES (25 ng/ml; 3 nM). Maximal M ⌽ migration was observed with 100 pM C15, 10 nM C13, and 10 nM C11 and was PTX sensitive. C19, however, displayed no chemotactic activity at all concentrations tested (0.1 pM -500 nM; Fig. S1 E) . Thus, we were able to identify a chemerin-derived peptide that retains antiinfl ammatory activity but exhibits no chemotactic activity for M ⌽ s, indicating the existence of distinct function-specifi c components of chemerin that could be exploited therapeutically. The prochemerin-derived peptides C6 and C8, which were found to be devoid of M ⌽ antiinfl ammatory activity, were also incapable of inducing M ⌽ migration at all concentrations tested (0.1 pM -500 nM; Fig. S1 , F and G).
Ablation of the ChemR23 gene impairs antiinfl ammatory and chemotactic effects of chemerin and C15
We next investigated whether the eff ects of chemerin and C15 in our in vitro models of M ⌽ activation and chemotaxis models, including sulfonic acid -induced colitis and zymosaninduced peritonitis ( 11, 13 ) .
We show for the fi rst time that chemerin undergoes proteolytic cleavage to generate potent antiinfl ammatory products that can exert profound antiinfl ammatory eff ects in vitro at low picomolar concentrations. A single injection of a synthetic chemerin-derived peptide signifi cantly reduces zymosaninduced peritonitis, and injection of an anti-chemerin antibody (ChAb) increases neutrophil and monocyte recruitment by up to 170%.
RESULTS AND DISCUSSION
Chemerin exerts antiinfl ammatory effects on activated M ⌽ s in a proteolysis-dependent manner To investigate the potential antiinfl ammatory action of chemerin, we fi rst evaluated the eff ect of murine chemerin on the production of infl ammatory mediators by peritoneal M ⌽ s (PM ⌽ s) elicited by Bio-Gel polyacrylamide beads and stimulated with LPS and IFN-␥ . PM ⌽ s were pretreated with chemerin for 1 h followed by a 15-h challenge with LPS/ IFN-␥ to induce classical M ⌽ activation. Chemerin inhibited the production of the proinfl ammatory mediators TNF-␣ (70%), IL-1 ␤ (60%), IL-6 (42%), IL-12 p40 (54%), and RANTES (40%) by classically activated M ⌽ s ( Fig. 1 A ) . In addition, chemerin induced the expression of mRNA for the antiinfl ammatory cytokines TGF-␤ (twofold) and IL-10 (10-fold). These eff ects were dose dependent, with maximal responses observed at 1 pM ( Fig. 1 A ) , and pertussis toxin (PTX) sensitive, indicating the involvement of a G ␣ i -linked GPCR ( Fig. 1 B ) . In addition, antiinfl ammatory eff ects were observed at 4, 8, and 15 h after LPS/IFN-␥ administration and were abrogated by PTX at all time points ( Fig. 1 C ) .
Previous studies have demonstrated that serine proteases released by granulocytes upon degranulation cleave the Cterminal extremity of prochemerin and release its chemotactic potential ( 6 ) . We therefore investigated the possibility that murine chemerin could undergo proteolytic processing by enzymes released upon murine M ⌽ activation. Coadministration of chemerin with leupeptin (a serine and cysteine protease inhibitor) or E-64 (a cysteine protease inhibitor) abolished its antiinfl ammatory eff ects ( Fig. 1 D ) , whereas the acidic protease inhibitor pepstatin A and the serine protease inhibitor pefabloc exerted no eff ect on chemerin-mediated suppression of M ⌽ activation. These data demonstrate that chemerin exerts inhibitory eff ects on M ⌽ activation in a cysteine protease -dependent manner. A cathepsin L inhibitor (Z-FF-FMK), cathepsin S inhibitor (Z-FL-COCHO), and a calpain I and II inhibitor (calpeptin) were used to further probe the specifi c cysteine proteases involved in chemerin cleavage. It was found that chemerin ' s antiinfl ammatory effects were dependent on calpains and cathepsin S but were independent of cathepsin L. Collectively, our results demonstrate for the fi rst time that classically activated M ⌽ s are capable of converting chemerin into potent antiinfl ammatory peptides by cysteine protease -mediated cleavage of the parent molecule, most likely involving calpains and cathepsin S. h. ***, P < 0.001; **, P < 0.01; *, P < 0.05 relative to LPS/IFN-␥ -treated samples; ###, P < 0.001; ##, P < 0.01; #, P < 0.05 relative to chemerin-treated samples. Graphs show mean values ± SEM from three to eight independent experiments. nd, below limit of detection for this assay. ns, not signifi cant.
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The chemotactic eff ects of chemerin and C15 were completely ablated in ChemR23 KO M ⌽ s, indicating that induction of M ⌽ chemotaxis by chemerin and C15 is entirely ChemR23 dependent ( Fig. 2 , A and B ). M ⌽ migration toward prototypical chemoattractants RANTES and fMLP was unaff ected in M ⌽ s from ChemR23 Ϫ / Ϫ mice (Fig. S2 , F and G), demonstrating that ChemR23 Ϫ / Ϫ M ⌽ s exhibited selective impairment of chemerin and C15-mediated chemotaxis.
C15 was unable to suppress proinfl ammatory mediator production by ChemR23 KO M ⌽ s, indicating that its were mediated via the chemerin receptor ChemR23 through the use of KO mice. PCR and Southern blot analysis confi rmed the presence of a disrupted ChemR23 allele in heterozygote and homozygote KO mice and the presence of a wild-type ChemR23 allele in heterozygote and wild-type animals ( Cytokine  Chemerin  C6  C8  C11  C13  C15  C15-S  C15-M  C19  N19  M20  TNF-␣  70  0  0  0  10  61  0  0  21  0  0  RANTES  40  0  0  0  32  47  0  0 
Table I. Antiinfl ammatory activity of chemerin-derived peptides

Percentage inhibition of LPS/IFN-␥ -induced infl ammatory cytokine expression
PM ⌽ s were challenged with 100 ng/ml LPS and 20 ng/ml IFN-␥ for 15 h with or without pretreatment with peptides (0.1 pM -100 nM) for 1 h. Where peptides exhibited antiinfl ammatory properties, percentage inhibition of LPS/IFN-␥ -induced M ⌽ activation represents effect with optimal dose (1 pM chemerin and C15 or 100 pM C13 and C19 Filters were fi xed in 4% formalin, and migrated cell nuclei were stained with DAPI, visualized, and quantifi ed. Serum-free medium was used as a negative control and 25 ng/ml RANTES (migration index, 6 ± 0.59) as a positive control. Graphs indicate mean migration index ± SEM for each treatment group ( n = 4 independent experiments). ***, P < 0.001; **, P < 0.01; *, P < 0.05 relative to migration induced by the same concentration of chemoattractant in ChemR23 Ϫ / Ϫ PM ⌽ s. (C and D) PM ⌽ s from wild-type and ChemR23 Ϫ / Ϫ mice were pretreated with 0.1 -1 pM C15 (C) or 0.1 -1 pM chemerin (D) for 1 h and then stimulated with 100 ng/ml LPS and 20 ng/ml IFN-␥ for 15 h. Mean expression of cytokines ± SEM in M ⌽ supernatants after 16 h was determined by ELISA ( n = 4 independent experiments). **, P < 0.01; *, P < 0.05 relative to LPS/IFN-␥ -treated samples. ns, not signifi cant. Fig. 3 E ) . C15 administration also diminished peritoneal expression of proinfl ammatory cytokines at 4 h, including TNF-␣ (51%), IL-1 ␤ (67%), IL-6 (67%), JE (59%), and KC (38%; Fig. 3 F ) . Control peptides C15-S and C15-M, which were devoid of in vitro antiinfl ammatory activity ( Table I ) , were not protective in vivo when given at the same dose and time as C15, as judged by neutrophil and monocyte levels ( Fig. 3, C and D ) . Suppression of neutrophil (1.9 × 10 6 to 0.83 × 10 6 cells; 60% decrease) and monocyte recruitment (0.69 × 10 6 to 0.42 × 10 6 cells; 42% decrease) was still seen 4 h after zymosan, when the same dose of C15 was given 2 h after zymosan injection ( Fig. 3 G ) . This demonstrates that C15 can reduce neutrophil and monocyte recruitment in an established infl ammatory setting, providing another indication that C15/C15 derivatives may represent attractive pharmacophores targeting infl ammatory pathologies. When the same experiments were performed in ChemR23 Ϫ / Ϫ mice, C15 administration was not able to suppress zymosan-induced monocyte and neutrophil recruitment, indicating complete dependence of C15 ' s antiinfl ammatory eff ects upon ChemR23 ( Fig. 3 H ) . Furthermore, the infl ammatory response of ChemR23 Ϫ / Ϫ mice to zymosan was equivalent in magnitude to that of the wild-type controls in terms of neutrophil ( +/+ , 5.7 ± 0.37 vs. Ϫ / Ϫ , 5.5 ± 0.63 cells) and monocyte recruitment ( +/+ , 1.05 ± 0.09 vs. Ϫ / Ϫ , 0.96 ± 0.11 cells; Fig. 3 H ) .
Blockade of endogenous chemerin species exacerbates peritoneal infl ammation
Given the apparent lack of ChemR23 Ϫ / Ϫ phenotype in the zymosan-induced peritonitis model, we investigated a potential endogenous role for chemerin/chemerin-derived peptides by injecting mice i.p. with a neutralizing polyclonal ChAb or a control IgG 1 h before a 4-or 24-h zymosan challenge. We had previously shown that ChAb but not control IgG was capable of inhibiting C15 and chemerin-induced M ⌽ chemotaxis and antiinfl ammatory eff ects in vitro ( Fig. 4, A and B ) . In vivo it was found that neutralization of endogenous chemerin species resulted in a rise in peritoneal neutrophil (63%) and monocyte (45%) levels at the 4-h time point relative to control IgG -treated mice and a 170 and 86% increase in peritoneal neutrophil and monocyte levels 24 h after zymosan injection ( Fig. 4, C and D ) . This exacerbation of peritoneal infl ammation over a 24-h period suggests an important antiinfl ammatory role for endogenous chemerin species in vivo in controlling the magnitude of the innate immune response. The absence of an exaggerated infl ammatory phenotype in ChemR23 Ϫ / Ϫ mice may be due to redundancy in the chemerin antiinfl ammatory system. In fact, an additional receptor for chemerin, antiinfl ammatory eff ects in this model are completely mediated through ChemR23 ( Fig. 2 C ) . Interestingly, chemerin displayed a reduced but not completely abrogated antiinfl ammatory activity on ChemR23 Ϫ / Ϫ M ⌽ s ( Fig. 2 D ) . These data are consistent with a model in which chemerin is cleaved by M ⌽ -derived proteases to generate antiinfl ammatory peptides that act through multiple GPCRs, including but not exclusively ChemR23. At the time of writing, a second receptor for chemerin, the GPCR GPR1, has been identifi ed ( 10 ) .
C15 ameliorates zymosan-induced peritonitis in a ChemR23-dependent manner
The zymosan -peritonitis model (for review see reference 15 ) has been used to demonstrate the antiinfl ammatory properties of dexamethasone ( 16 ) , annexin peptide ( 17 ) , and the lipid ChemR23 agonist RvE1 ( 13 ), which typically suppress both infl ammatory cell recruitment into the peritoneal cavity and proinfl ammatory cytokine production.
Given the high chemotactic potential of chemerin and inherent requirement for proteolysis, we turned to the Cterminal synthetic peptide C15 for in vivo characterization of antiinfl ammatory eff ects in the sterile peritonitis model because C15 is largely devoid of chemotactic activity (Fig. S1 B) yet exerts comparable antiinfl ammatory eff ects to those of proteolyzed chemerin ( Table I ) . To determine the antiinfl ammatory properties of C15 in vivo, a time-course experiment was performed extending over 48 h. Neutrophil (7/4 high , Ly-6G high ) and monocyte (7/4 high , Ly-6G low ) populations in peritoneal lavage fl uid were determined by FACS analysis according to established protocols ( 18, 19 ) . Administration of zymosan i.p. produced a time-dependent extravasation of infl ammatory cells into the peritoneal cavity, which followed the typical profi le of an acute infl ammatory response ( Fig. 3, A and B , solid line). Pretreatment with C15 (8 pg/ mouse; ‫ف‬ 0.32 ng/kg) 1 h before zymosan challenge brought the peak neutrophilia forward from 4 h post-zymosan administration to 2 h with ‫ف‬ 50% the magnitude of that of zymosan-challenged mice (reduced from 1.25 × 10 6 to 0.62 × 10 6 cells; Fig. 3 A , dotted line) . Suppression of neutrophil infi ltration by C15 was seen at 2, (50%), 4 (66%), and 24 h (50%). A single dose of C15 peptide was also eff ective in reducing monocyte levels in infl amed cavities at all time points, with > 60% suppression seen at 4 (63%), 8 (61%), and 48 h (64%; Fig. 3 B , dotted line) . The rate of monocyte infi ltration was highest 2 -4 h after zymosan injection (0.51 × 10 6 cells/h), and C15 administration reduced the rate of infl ux (0.18 × 10 6 cells/h). A single dose of C15 peptide before zymosan challenge therefore provided signifi cant protection against zymosan-induced peritoneal infl ammation over 48 h.
The time-course experiment identifi ed the 4-h postzymosan time point as an appropriate point for validation of C15 ' s antiinfl ammatory activity. In this study, a single dose of C15 produced a dose-dependent reduction in zymosan-elicited neutrophil and monocyte recruitment, which was maximal at 8 pg/mouse C15 ( ‫ف‬ 0.32 ng/kg; Fig. 3 , C -E , and Fig. S3 , which is available at http://www.jem.org/cgi/content/full/ native hypothesis is that the ChemR23 infl ammatory axis may be of particular importance only in certain infl ammatory pathologies or that a ChemR23 KO phenotype may not manifest except in the context of chronic infl ammation.
the GPCR GPR1, has now been reported, which may represent a second target for chemerin-derived peptides ( 10 ) . We therefore predict that ablation of the chemerin gene may result in mice with exaggerated infl ammatory pathologies. An alter- Figure 3 . C15 ameliorates zymosan-induced peritonitis in a ChemR23-dependent manner. C57Bl6/J mice were dosed i.p. with PBS or 0.32 ng/kg C15 followed by injection with PBS or 10 μ g zymosan ( ‫ف‬ 2 × 10 6 particles per cavity) 1 h later. Peritoneal exudate cells (PECs) were harvested by peritoneal lavage at multiple time points (A and B; fi ve to six mice/group) or after 4 h (C -E; 6 -15 mice/group). Total PECs were quantifi ed, and cellular composition (neutrophils vs. monocytes) was determined by FACS analysis. Cells were stained with Ly-6G-PE and 7/4-FITC. Gates were constructed around two populations, the neutrophils (7/4 high , Ly-6G high ) and monocytes (7/4 high , Ly-6G low ). (E) Representative FACS plots are shown for each treatment group at 4 h after zymosan injection. (F) Peritoneal lavage fl uid was assayed for TNF-␣ , KC, IL-6, IL-1 ␤ , and JE by Luminex assay. (G) Mice (six to eight/treatment) were dosed i.p. with 10 μ g zymosan and with 8 pg C15 or PBS either 1 h beforehand (C15 pretreatment) or 2 h later (C15 post-zymosan). Peritoneal lavage was performed 4 h after zymosan challenge. (H) Wild-type and ChemR23 Ϫ / Ϫ mice on a 129SvEv background were dosed i.p. with PBS or 0.32 ng/kg C15 followed by injection with PBS or 10 μ g zymosan 1 h later. PECs cells were harvested by peritoneal lavage 4 h after zymosan injection and characterized by FACS (six to eight mice/treatment). C15, chemerin15; Z, zymosan; ***, P < 0.001; **, P < 0.01 relative to zymosan-treated animals; nd, not detectable; ns, not signifi cant.
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peritoneal exudates by up to 25% when administered at 300 ng/ mouse i.p. (12 μ g/kg) ( 23 ) . The in vitro and in vivo concentrations of chemerin used in our experiments are ‫ف‬ 500-fold lower than concentrations of chemerin found in murine plasma and serum ( 8 ) . This could mean that little endogenous chemerin may need to be present at sites of infl ammation for antiinfl ammatory eff ects to become evident in vivo.
Here, we have demonstrated that chemerin exhibits antiinfl ammatory eff ects on M ⌽ s in vitro in a proteolysis-dependent fashion. We found that C-terminal chemerin peptides, in particular C15, exhibit potent antiinfl ammatory properties in in vitro and in vivo models of infl ammation when administered in the picogram range that are mediated through ChemR23. These fi ndings suggest that C15/C15 derivatives may represent a novel therapeutic strategy for the treatment of infl ammatory pathologies via ChemR23.
C-terminal chemerin peptides: novel antiinfl ammatory mediators
Many endogenous proinfl ammatory mediators have been described, several of which are active in the picomolar range, including TNF-␣ (10 Ϫ 11 M), fMLP (10 Ϫ 11 M), and IL-1 (10 Ϫ 14 M) ( 20, 21 ) . To our knowledge, our synthetic chemerin peptides are the fi rst antiinfl ammatory mediators shown to be active in vitro and in vivo in the picomolar range. Pharmaceutical preparations such as dexamethasone are commonly administered at concentrations in the micromolar range in vitro ( 22 ) . Indeed, dexamethasone achieves a 50% suppression of monocyte and neutrophil infl ux in the zymosan-induced peritonitis model at 30 μ g/mouse (1.2 mg/kg) ( 16 ), whereas C15 produces equivalent antiinfl ammatory eff ects at a dose of 8 pg/ mouse (0.32 ng/kg). C15 is also more potent than the lipid ligand for ChemR23, RvE1, which reduces PMN numbers in Fig. 2 ) and allowed to migrate toward RANTES, chemerin, or C15 ± ChAb or control IgG. Graphs indicate mean migration index ± SEM ( n = 4 independent experiments). ***, P < 0.001; **, P < 0.01 relative to chemoattractant. (B) PM ⌽ s were pretreated with 1 pM C15 or 1 pM chemerin ± ChAb or control IgG for 1 h and then stimulated with 100 ng/ml LPS and 20 ng/ml IFN-␥ for 15 h. Mean expression of RANTES ± SEM in M ⌽ supernatants after 16 h was determined by ELISA ( n = 4 independent experiments). ***, P < 0.001 relative to LPS/IFN-␥ -treated samples. (C and D) C57Bl6/J mice were dosed i.p. with PBS, 100 ng/mouse ChAb, or 100 ng/mouse control IgG followed by injection with PBS or 10 μ g/cavity zymosan 1 h later. PECs were harvested 4 and 24 h after zymosan injection and processed as outlined in Fig. 3 . Z, zymosan; ChAb, anti-chemerin antibody; **, P < 0.01 relative to zymosan-challenged mice; ns, not signifi cant.
composition (neutrophils vs. monocytes) of peritoneal lavage fl uid were obtained by FACS analysis. In brief, 10 5 cells were blocked with anti -mouse 2.4G2 Fc ␥ II/III (0.5 μ g/0.10 5 cells; Serotech) for 10 min and stained for 10 min with FITC-conjugated anti -mouse 7/4 and PE-conjugated anti -mouse Ly-6G (0.5 μ g/0.5 × 10 6 cells; clones rmC5-3 and RB6-8C5, respectively; BD Biosciences). Gates were constructed around two populations, the neutrophils (7/4 high , Ly-6G high ) and infl ammatory monocytes (7/4 high , Ly-6G low ). The percentage of total events in each population was obtained. In addition, cell-free lavage fl uid was collected for use in ELISAs and Luminex assays.
Generation and characterization of ChemR23 ؊ / ؊ mice. ChemR23 is encoded by the Cmklr1 gene (Ensembl Gene ID, ENSMUSG00000042190). The gene-targeting vector was designed to delete the majority of the coding sequence from 33 bp after the initiating methionine to beyond the translational stop codon, thereby removing all but the fi rst 12 of the 371 protein residues and replacing them with an internal ribosome entry site LacZ reporter gene. Targeted embryonic stem cell clones were identifi ed by PCR and confi rmed by Southern blot analysis. Correctly targeted clones were used to generate chimeras that transmitted the ChemR23 KO allele at the expected Mendelian frequency. Heterozygous mice were viable and fertile as were the homozygous KO mice. PCR was performed with the following primers: P1, 5 Ј -CCCAGTCACAGGAGCTTCACCAAGATG-3 Ј ; p2, 5 Ј -AATGGCCGCTTTTCTGGATTCATCGAC-3 Ј ; and p3, 5 Ј -ATG-AGCCGCCTTGTGCAAAATTCAGTG-3 Ј . DNA fragments were analyzed by agarose gel electrophoresis. A product of 378 bp (neomycin insert) corresponded to the Ϫ / Ϫ genotype, a 215 bp product (ChemR23) corresponded to the + / + genotype, and the presence of both the 215-and 378-bp products indicated the Ϫ /+ genotype.
Calcium fl ux. 4-d Bio-Gel -elicited cells were harvested and resuspended in HBSS with CaCl 2 and MgCl supplemented with 0.5% BSA and 10 mM Hepes (HBSS/BSA) at room temperature to a cell density of 10 7 cells/ml. The cell suspension was incubated with 2 μ M Fura-PE3/AM (EMD) for 45 min at room temperature. The cells were then washed twice and resuspended in HBSS/BSA (3 × 10 7 cells/ml). 100 μ l of cell suspension (3 × 10 6 cells) was added to a cuvette containing 400 μ l of prewarmed (37 ° C) HBSS/ BSA and placed in a luminescence spectrometer (LS55; PerkinElmer). After a period of at least 60 s, fl uorescence measurements were recorded at excitation wavelengths of 340 and 380 nm and an emission wavelength of 510 nm. 10 μ l of agonist was added under constant stirring at appropriate intervals. At the end of each experiment, 10 μ l 10% Triton X-100 was added to determine maximum calcium fl ux.
Statistics. Student ' s t test and one-way ANOVA (with Tukeys post-hoc test) were performed using GraphPad Prism software.
Online supplemental material. Fig. S1 shows M ⌽ chemotaxis induced by chemerin and chemerin-derived peptides. Fig. S2 provides detailed methods for the generation and characterization of ChemR23 Ϫ / Ϫ mice, including Southern blots and targeting constructs, Ca 2+ fl ux, and chemotaxis data. Fig. S3 shows the dose-dependent antiinfl ammatory eff ects of C15 in zymosan-induced peritonitis. M ⌽ activation assays. Bio-Gel P100 polyacrylamide beads (1 ml of 2% wt/ vol in PBS; Bio-Rad Laboratories) were injected into the peritoneal cavity of 8 -12-wk-old C57BL/6 mice. 4 d later, mice were killed and peritoneal exudates collected in PBS plus 2 mM EDTA. Harvested cells were centrifuged and resuspended in OptiMEM medium (Invitrogen) supplemented with 2 mM glutamine (Invitrogen), 50 U/ml penicillin, and 50 μ g/ ml streptomycin (Invitrogen). Cells (1.5 × 10 6 /well) were plated in six-well tissue culture plates (35-mm diameter; Costar) and allowed to adhere for 2 h at 37 ° C in a humidifi ed atmosphere containing 5% CO 2 to isolate M ⌽ populations by adherence. Nonadherent cells were removed by washing with PBS after 2 h. Adherent cells were judged to be > 95% M ⌽ s by morphological criteria. M ⌽ s were preincubated with 10 Ϫ 12 -10 Ϫ 8 M rmChemerin (R & D Systems), 10 Ϫ 12 -10 Ϫ 8 M chemerin peptides (Bio-Synthesis Inc.), or 1 μ M dexamethasone (Sigma-Aldrich) for 1 h and then challenged with 100 ng/ml LPS (Sigma-Aldrich) and 20 ng/ml IFN-␥ (PeproTech) for 15 h. Protease inhibitors (Sigma-Aldrich and EMD) were administered with chemerin to determine dependency upon proteolysis. M ⌽ media were harvested and stored at Ϫ 80 ° C until use in ELISAs (R & D Systems) and Luminex assays (Bio-Rad Laboratories). Protease inhibitors were used at the following concentrations: leupeptin, 15 μ g/ml; E-64, 5 μ M; pefabloc, 10 μ M; pepstatin A, 1 μ M; calpeptin, 5 μ M; cathepsin S inhibitor, 250 nM; cathepsin L inhibitor, 1 μ M. Chemerin peptides were prepared by Bio-Synthesis Inc., and purity was assessed to be > 95% as assessed by HPLC and mass spectrometry (data provided by the manufacturer). Chemerin and chemerin-derived peptides were not found to aff ect cell viability adversely as determined using the MTS assay (Promega) and had no detectable endotoxin as judged by Limulus amebocyte lysate assay (Cambrex).
Detection of secreted protein by ELISAs and Luminex. RANTES, TNF-␣ , and KC concentrations in cell supernatants and peritoneal fl uid were assessed by ELISA (R & D Systems). IL-12 p40, IL-1 ␤ , TNF-␣ , JE, and IL-6 levels were determined by Luminex multiplex bead assay (Bio-Rad 6 plex assay). Detection limits were 100 pg/ml for ELISAs and 10 -50 pg/ml for Luminex assays depending on cytokine.
RNA preparation and RT-PCR. Total RNA was extracted using QIAGEN RNeasy kits, reverse transcribed, and subjected to quantitative RT-PCR using the Sybr-Green method. Data were analyzed using the 2 Ϫ ⌬ ⌬ CT method ( 24 ) .
Chemotaxis assay. 4 × 10 5 Bio-Gel-elicited M ⌽ s were harvested and placed on 96-well Neuroprobe membranes (6-mm diameter, 8-μ m pore size; ChemoTX) in RPMI supplemented with 25 mM Hepes (Invitrogen) and 0.1% BSA (Sigma-Aldrich). Cells were allowed to migrate toward 1 pM -100 nM chemerin peptides, 1 pM -50 nM chemerin, 25 ng/ml RANTES (PeproTech), or serum-free media for 4 h. Signal transduction via G ␣ i was blocked by preincubating cells with 200 ng/ml PTX (Sigma-Aldrich) for 30 min before chemotaxis assays. Migrated cells on the underside of membranes were fi xed (3% formalin) and stained with DAPI. Migration was quantifi ed as total pixel count of DAPI (Sigma-Aldrich) -stained nuclei under the fl uorescence microscope (two photos/membrane and a minimum of three replicate wells per treatment). Images were analyzed using Metamorph software to determine percentage threshold areas (TA) occupied by migrated cells. Migration indices were obtained by dividing treatment TA by serum-free media TA.
Murine peritonitis. C57BL6/J mice were administered 500 μ l C15 (0.32 ng/ kg) or vehicle (PBS) i.p. 1 h before administration of 500 μ l of 10 μ g zymosan A (Sigma-Aldrich) i.p. After 2, 4, 8, 16, 24 , and 48 h and after mice were killed, peritoneal exudates were collected by peritoneal lavage with 5 ml of sterile PBS-3 mM EDTA. Total cell counts were determined, and the cellular
